PBH Stock Analysis: Buy, Sell, or Hold?
PBH - Prestige Consumer Healthcare Inc.
$46.91
0.16 (0.34%)
▲
5d:
-7.38%
30d:
-19.3%
90d:
-29.21%
HOLD
MODERATE Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 13, 2026
0d
Get Alerted When PBH Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: PBH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
📊 HOLD: PBH shows mixed signals. Fine to hold existing positions. Not urgent to buy or sell.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$77.30
Based on 4.8% avg growth
INTRINSIC VALUE TODAY
$48.00
2.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 12.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: PBH is currently trading at $46.91, which is considered oversold relative to its 30-day fair value range of $52.05 to $58.52. From a valuation perspective, the stock is trading at a discount (Forward PE: 9.8) compared to its historical average (12.8). Remarkably, the market is currently pricing in an annual earnings decline of 8.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, PBH is in a downtrend. Immediate support is located at $42.62, while resistance sits at $56.59.
Market Sentiment: PBH has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $76.50 (+63.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, PBH is in a downtrend. Immediate support is located at $42.62, while resistance sits at $56.59.
Market Sentiment: PBH has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $76.50 (+63.6%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$52.05 -
$58.52
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 63.6% below Wall St target ($76.50)
- CAUTION: 5-day price weakness (-7.4%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$52.05 -
$58.52
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$42.62
Resistance Level
$56.59
Current Trend
Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.76
Wall Street Target
$76.50
(+63.6%)
Revenue Growth (YoY)
-2.4%
Earnings Growth (YoY)
-20.5%
Profit Margin
16.9%
Valuation Discount vs History
-8.8% cheaper
PE vs Historical
9.8 vs 12.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.8%
(market-implied from PE analysis)
1-Year Target
$42.64
(-9%)
2-Year Target
$38.88
(-17%)
3-Year Target
$35.46
(-24%)
3-Yr Target (if PE normalizes)
(PE: 10→13)
$46.50
(-1%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.1, Growth: 5.5%)
$124.03
(+165%)
Base:
(SPY PE: 9.8, Growth: 5.5%)
$54.86
(+17%)
Bear:
(PE: 8.3, Growth: 5.5%)
$46.64
(0%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (12x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 12.12 | Current EPS (TTM): $3.79
Bull Case
$63.84
(+37%)
Analyst growth 26.4%, PE expands to 13.3
Base Case
$58.03
(+24%)
Market implied 26.4%, PE stable at 12.1
Bear Case
$31.23
(-33%)
Severe decline -20.0%, PE contracts to 10.3
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 9.8 to 12.8
Stabilization Target:
$61.30
(+31.1%)
PE Expansion Potential:
+31.1%
Share & Embed Analysis
Last updated: May 18, 2026 11:55 AM ET
Data refreshes hourly during market hours. Next update: 12:55 PM
Data refreshes hourly during market hours. Next update: 12:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PBH showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jeffrey Zerillo
SELL
1000 shares
2026-02-11
Jeffrey Zerillo
SELL
281 shares
2025-12-01
Jeffrey Zerillo
SELL
719 shares
2025-11-28
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$131 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 58 HOLD |
